AstraZeneca's blockbuster cancer drug gains EU approval

December 18, 2014 8:24 AM

2 0

AstraZeneca's blockbuster cancer drug gains EU approval

AstraZeneca has gained approval to market its blockbuster ovarian cancer drug Lynparza across Europe.

The orally taken drug is used to treat specific strains of ovarian cancer, particularly mutated or relapsed forms of the disease, and the European Commission's clinical trials found it 'significantly prolonged [patient's] progression-free survival'.

Read more

To category page

Loading...